![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RBFOX2 |
Gene summary for RBFOX2 |
![]() |
Gene information | Species | Human | Gene symbol | RBFOX2 | Gene ID | 23543 |
Gene name | RNA binding fox-1 homolog 2 | |
Gene Alias | FOX2 | |
Cytomap | 22q12.3 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | O43251 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23543 | RBFOX2 | CA_HPV_3 | Human | Cervix | CC | 4.95e-04 | 1.70e-01 | 0.0414 |
23543 | RBFOX2 | CCI_1 | Human | Cervix | CC | 7.99e-16 | 1.70e+00 | 0.528 |
23543 | RBFOX2 | CCI_2 | Human | Cervix | CC | 2.32e-10 | 1.25e+00 | 0.5249 |
23543 | RBFOX2 | CCI_3 | Human | Cervix | CC | 1.03e-24 | 1.37e+00 | 0.516 |
23543 | RBFOX2 | sample3 | Human | Cervix | CC | 4.63e-06 | 2.08e-01 | 0.1387 |
23543 | RBFOX2 | T3 | Human | Cervix | CC | 4.77e-04 | 1.92e-01 | 0.1389 |
23543 | RBFOX2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.28e-41 | 1.22e+00 | 0.0155 |
23543 | RBFOX2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.55e-37 | 2.23e+00 | -0.1808 |
23543 | RBFOX2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.23e-32 | 2.85e+00 | 0.0216 |
23543 | RBFOX2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.35e-37 | 2.30e+00 | -0.0811 |
23543 | RBFOX2 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.14e-11 | 7.39e-01 | -0.1088 |
23543 | RBFOX2 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.79e-43 | 2.28e+00 | -0.1954 |
23543 | RBFOX2 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.88e-34 | 2.91e+00 | -0.2602 |
23543 | RBFOX2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.42e-20 | 2.32e+00 | -0.2196 |
23543 | RBFOX2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.94e-33 | 2.64e+00 | -0.1207 |
23543 | RBFOX2 | HTA11_83_2000001011 | Human | Colorectum | SER | 5.46e-33 | 2.16e+00 | -0.1526 |
23543 | RBFOX2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.85e-67 | 2.73e+00 | -0.1464 |
23543 | RBFOX2 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.98e-51 | 2.51e+00 | -0.1001 |
23543 | RBFOX2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.30e-47 | 2.97e+00 | -0.059 |
23543 | RBFOX2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.28e-35 | 2.51e+00 | -0.1706 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
GO:004854510 | Cervix | CC | response to steroid hormone | 74/2311 | 339/18723 | 5.71e-07 | 2.09e-05 | 74 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:003021810 | Cervix | CC | erythrocyte differentiation | 34/2311 | 120/18723 | 2.00e-06 | 6.18e-05 | 34 |
GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
GO:00456468 | Cervix | CC | regulation of erythrocyte differentiation | 17/2311 | 47/18723 | 2.38e-05 | 4.16e-04 | 17 |
GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:00713839 | Cervix | CC | cellular response to steroid hormone stimulus | 40/2311 | 204/18723 | 1.93e-03 | 1.42e-02 | 40 |
GO:00488135 | Cervix | CC | dendrite morphogenesis | 30/2311 | 146/18723 | 3.27e-03 | 2.13e-02 | 30 |
GO:00305188 | Cervix | CC | intracellular steroid hormone receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RBFOX2 | SNV | Missense_Mutation | c.1051N>T | p.Arg351Trp | p.R351W | O43251 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RBFOX2 | SNV | Missense_Mutation | novel | c.1010N>T | p.Thr337Met | p.T337M | O43251 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RBFOX2 | SNV | Missense_Mutation | novel | c.512G>A | p.Ser171Asn | p.S171N | O43251 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RBFOX2 | SNV | Missense_Mutation | c.241A>G | p.Asn81Asp | p.N81D | O43251 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.979) | TCGA-44-3918-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
RBFOX2 | SNV | Missense_Mutation | novel | c.1085N>T | p.Pro362Leu | p.P362L | O43251 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-55-A4DG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RBFOX2 | SNV | Missense_Mutation | novel | c.328N>T | p.Thr110Ser | p.T110S | O43251 | protein_coding | deleterious(0.03) | benign(0.389) | TCGA-86-8674-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD |
RBFOX2 | SNV | Missense_Mutation | c.1108N>T | p.Gly370Cys | p.G370C | O43251 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RBFOX2 | SNV | Missense_Mutation | c.708N>T | p.Arg236Ser | p.R236S | O43251 | protein_coding | deleterious(0.01) | benign(0.295) | TCGA-51-4079-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RBFOX2 | SNV | Missense_Mutation | novel | c.979N>T | p.Pro327Ser | p.P327S | O43251 | protein_coding | deleterious(0.03) | possibly_damaging(0.84) | TCGA-60-2714-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
RBFOX2 | SNV | Missense_Mutation | novel | c.1328N>C | p.Gly443Ala | p.G443A | O43251 | protein_coding | tolerated(0.13) | probably_damaging(0.994) | TCGA-66-2769-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |